Compare General Motors Company (GM) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Globus Medical Inc. Class A Common Stock — how do they compare? General Motors Company trades at $83.17 (market cap $73.71B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: General Motors Company is far larger — about 7.2× Globus Medical Inc. Class A Common Stock's market cap, and General Motors Company pays a 0.86% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| GM | GMED | |
|---|---|---|
Market Cap | $73.71B | $10.25B |
Volume | 6,224,747 | 1,108,124 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $96.82 |
52-Week Low | $57.34 | $58.33 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $176.68B | $9.76B |
Dividend Yield | 0.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $83.05, up 0.83% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, though Q3 2026 results are pending. Valuation metrics appear reasonable with P/S of 0.42 and P/B of 1.19, while profitability remains modest with 1.05% net margin. Recent news highlights competitive pressures as Toyota narrows the U.S. sales gap and Q3 vehicle sales declined 5.5%.
GM faces near-term headwinds from declining sales and margin pressure, but analyst consensus remains bullish with a $102.33 price target representing 23% upside. The company benefits from regulatory savings and EV partnerships, though execution risks and market share erosion require monitoring. Cash flow stability and dividend payments provide shareholder support amid industry transition challenges.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
